J Neuropsychiatry Clin Neurosci 16:119-120, February 2004
© 2004 American Psychiatric Press, Inc.
Delirium Induced by Abrupt Discontinuation of Paroxetine
Yuji Hayakawa, M.D., Department of Psychiatry, Akita University School of Medicine, 1-1-1 Hondo, Akita010-8543, Japan,
Atsushi Sekine, M.D., Department of Psychiatry, Akita University School of Medicine, 1-1-1 Hondo, Akita010-8543, Japan and
Tetsuo Shimizu, M.D., Department of Psychiatry, Akita University School of Medicine, 1-1-1 Hondo, Akita010-8543, Japan
Case Report
SIR: The patient was a 73-year-old woman who developed major depression triggered by domestic stress in June 2002. She was prescribed 40 mg of paroxetine and 0.8 mg of alprazolam at bedtime and 3 mg of etizolam during the day. Full remission resulted, and treatment was maintained.
The patient remained well until August 2002, when she was admitted to the urology department of a hospital as a kidney donor for her daughter. She received a last dosage of medication at bedtime on the day before surgery. At 07:00 the following day, diazepam (2 mg) and ranitidine hydrochloride (150 mg) were administered preoperatively. Left-side donor nephrectomy was performed following intravenous injection of thiopental (200 mg) at 10:00 and inhalation with sevoflurane for maintenance of general anesthesia. The operation was completed without complications at 14:00. By 14:30, the patient had completely regained consciousness. Post-operative laboratory data revealed no abnormalities. However, symptoms of thirst and dizziness were suddenly reported from 16:00. Thereafter, disorderly behavior gradually developed. At 21:20, a urologist administered etizolam (1 mg) and alprazolam (0.8 mg), but the patient remained agitated and complained of visual hallucinations such as insects. Since psychotic symptoms persisted despite intravenous injection of haloperidol (5 mg) at 22:25, diazepam (5 mg) at 23:40, and hydroxyzine hydrochloride (50 mg) at 01:57 the following day, the urologist referred the patient to a psychiatrist (the author) at 10:00 the next morning. Although visual hallucinations had disappeared, a diagnosis of delirium was made since the patient was assessed to be not fully oriented and was unable to follow verbal commands (Japan Coma Scale score = 1-3). Tiapride hydrochloride (75 mg) during the day and chlorpromazine (15 mg) at bedtime were prescribed and the patient slept well. Psychotic manifestations had resolved completely by 10:30 on postoperative day 2.
Comments
We attribute delirium in this case to the abrupt withdrawal of paroxetine, because: 1) the patient had been taking a relatively high dose of paroxetine for a prolonged period; 2) delirium appeared soon after cessation of paroxetine; 3) delirium developed despite absence of intraoperative complications; 4) delirium was preceded by thirst and dizziness, which are common symptoms of SSRI withdrawal;1 5) no drugs known to interact with paroxetine2 were administered intraoperatively; and 6) full recovery from delirium occurred within a short period. Another possible candidate for withdrawal delirium in this case was benzodiazepine. However, as psychotic manifestations were exacerbated despite administration of benzodiazepine before surgery and in the period when delirium initially appeared, discontinuation of benzodiazepine seems unlikely to have caused the delirium.
Paroxetine is reportedly more likely to induce withdrawal symptoms than other SSRIs, due to the following pharmacokinetics3,4,5: (1) short half-life; (2) absence of active metabolites; and (3) non-linear kinetics. Physicians should pay close attention to delirium as well as other symptoms of SSRIs, particularly in cases in whom high-dose paroxetine has been maintained for long periods.
REFERENCES
- Malya G, White K, Gunderson C: Is there a serotonergic withdrawal syndrome? Biol Psychiatry 1993; 33:851–852[CrossRef][Medline]
- Stanford BJ, Stanford SC: Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 2000; 14:186–188[Free Full Text]
- Dominguez RA, Goodnick PJ: Adverse events after the adrupt discontinuation of paroxetine. Pharmacotherapy 1995; 15:778–780[Medline]
- Price JS, Waller PC, Wood SM, et al.: A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors, including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42:757–763[CrossRef][Medline]
- Haddad P: Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 1997; 58:17–21
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Neuropsychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
